Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 1 4

Status

Completed 4Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Genitourinary 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Monoclonal Gammopathy of Undetermined Significance 1Castleman Disease 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × siltuximab × Clear all
NCT05665725 2025-01-31

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
11 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00412321 2014-07-01

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Centocor, Inc.

Phase 1 Completed
67 enrolled
LymphoidPlasma cell

Castleman Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00401765 2014-05-26

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Centocor, Inc.

Phase 1 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡